Straumann Reports Strong 4Q, Announces Plans for 2011
BY LAUREN UZDIENSKI, FEBRUARY 15, 2011
This morning Straumann reported 7% revenue growth in 4Q:10, accelerating from 3% in 3Q:10 and matching rebounding dental implant sales at Biomet and Zimmer. North American revenue growth, according to Straumann's press release, reached the double digits, an encouraging sign for an industry that has struggled in the recession.
Straumann is currently #1 in the dental implant space with about 19% of the market. They're trailed by Nobel Biocare. Straumann predicts that they will continue to take share in 2011, even though earnings may take a hit from the strengthening Swiss franc (most of Straumann's production is in Switzerland). The company added that they want to grow organically, particularly in their digital and regenerative segments. In their preliminary annual report, the company names new restorative materials, new abutment solutions and an "improved digital workflow" for implants as being in the pipeline for 2011, with an enhanced bone graft product in the lineup for 2012.
As for M&A? On the call, the company said they were "opportunistic" about potential acquisitions, including Astra Tech, though no decisions have been made.
